NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Contineum Therapeutics, Inc. (CTNM) Stock Analysis

Contineum Therapeutics, Inc. (CTNM) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CTNM

$16.70

−$0.87 (−4.95%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CTNM with… →

CTNM Key Statistics

As of Sep 4, 2026
Trading
Open
$17.38
Previous Close
$17.57
Day's Range
16.50–17.71
52-Week Range
8.60–17.79
Volume
346.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.75
Valuation
Market Cap
$628.27M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.72
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$59.98M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
32.96M
1-Year Return
+51.96%
Dividend and dates
Earnings Date
October 29, 2026estimated
Avg Volume
435.18K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CTNM Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+46.11%
2025−21.98%
2024 (partial year)−4.87%

As of September 4, 2026.

CTNM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$59.98M—
2024$0.00−$42.26M—
2023$50.00M$22.72M45.4%
2022$0.00−$24.25M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$68.06M−$59.98M—
2024$0.00—−$50.89M−$42.26M—
2023$50.00M—$16.08M$22.72M45.4%
2022$0.00—−$22.72M−$24.25M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CTNM Valuation vs Biotechnology Median

Median of 656 stocks
MetricCTNMBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Contineum Therapeutics, Inc. (CTNM) at $628.27M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 51 employees.

Over the past 52 weeks the price has ranged from $8.60 to $17.79. CTNM last closed at $16.70 on September 4, 2026. That is −$0.87 (−4.95%) against the previous close. The latest close sits 94.19% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $59.98M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −1.72.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the price has returned +51.96%. The stored price history starts on April 5, 2024, and the total return since then is +8.44%. The reported beta is 0.75. Annualized volatility over the trailing 2 years is 81.91%.

Growth & Income

The record shows no dividend for CTNM.

The record holds one complete calendar year, 2025, which returned −21.98%. So far in 2026 the price is +46.11%.

Peer Comparison

Contineum Therapeutics, Inc. (CTNM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Contineum Therapeutics, Inc. CTNM $628.27M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Contineum Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Contineum Therapeutics, Inc.

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is based in San Diego, California.

Visit website →